Cargando…

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane

BACKGROUND: Everolimus-related interstitial lung disease (ILD) (also: pneumonitis) poses a difficulty for physicians, as it is hard to discriminate ILD from other causes of respiratory symptoms and to decide on safe treatment continuation. OBJECTIVE: We investigated the capability of pulmonary funct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willemsen, Annelieke E. C. A. B., Tol, Jolien, van Erp, Nielka P., Jonker, Marianne A., de Boer, Maaike, Meek, Bob, de Jong, Paul C., van Moorsel, Coline, Gerritsen, Winald R., Grutters, Jan C., van Herpen, Carla M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684805/ https://www.ncbi.nlm.nih.gov/pubmed/31325105 http://dx.doi.org/10.1007/s11523-019-00656-2

Ejemplares similares

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

Clustering of lung diseases in the family of interstitial lung disease patients
por: Terwiel, Michelle, et al.
Publicado: (2022)

Non-specific and Usual Interstitial Pneumonia, Short-Term Survival After Surgical Biopsy
por: Knipscheer, Barbara J., et al.
Publicado: (2015)

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
por: Moll, Sofia A., et al.
Publicado: (2020)

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer
por: Willemsen, A. E. C. A. B., et al.
Publicado: (2017)

Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases
por: Moll, Sofia A., et al.
Publicado: (2022)

Understanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed Lungs
por: van Moorsel, Coline H. M., et al.
Publicado: (2015)

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Telomere shortening and DNA damage in culprit cells of different types of progressive fibrosing interstitial lung disease
por: van Batenburg, Aernoud A., et al.
Publicado: (2021)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Genetic disorders of the surfactant system: focus on adult disease
por: van Moorsel, Coline H.M., et al.
Publicado: (2021)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis
por: Spoorenberg, Simone M. C., et al.
Publicado: (2018)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis
por: Snetselaar, Reinier, et al.
Publicado: (2018)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy
por: Vorselaars, Adriane D. M., et al.
Publicado: (2013)

Systematic review of drug effects in humans and models with surfactant-processing disease
por: Klay, Dymph, et al.
Publicado: (2018)

Decreased Survival and Lung Function in Progressive Pulmonary Fibrosis
por: Platenburg, Mark G. J. P., et al.
Publicado: (2023)

Optimizing Screening for Early Disease Detection in Familial Pulmonary Fibrosis (FLORIS): A Prospective Cohort Study Design
por: Maus, Martijn T. K., et al.
Publicado: (2023)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study
por: Knapen, Lotte M., et al.
Publicado: (2018)

IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study
por: Korthagen, Nicoline M., et al.
Publicado: (2012)

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
por: Hoffman, Thijs W., et al.
Publicado: (2023)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

A genetic polymorphism in the CAV1 gene associates with the development of bronchiolitis obliterans syndrome after lung transplantation
por: Kastelijn, Elisabeth A, et al.
Publicado: (2011)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013)

ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis Patients
por: Karakaya, Bekir, et al.
Publicado: (2022)

Genetic Variant Overlap Analysis Identifies Established and Putative Genes Involved in Pulmonary Fibrosis
por: Groen, Karlijn, et al.
Publicado: (2023)

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2014)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Association between Variations in Cell Cycle Genes and Idiopathic Pulmonary Fibrosis
por: Korthagen, Nicoline M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i1pikc9e64f27vgddbirf0n9uo